A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer

Song, Jin; Ma, Shiyong; Sokoll, Lori J.; Eguez, Rodrigo Vargas; Höti, Naseruddin; Zhang, Hui; Mohr, Phaedre; Dua, Renu; Patil, Dattatraya; May, Kristen Douglas; Williams, Sierra; Arnold, Rebecca S.; Sanda, Martin G.; Chan, Daniel W.; Zhang, Zhen

doi:10.7150/thno.55676

Cited by 16 publications

(15 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that Foretinib simultaneously inhibited cancer cells and lymphatic endothelial cells to reduce pancreatic tumor growth in vivo, and suppressed angiogenesis and lymphangiogenesis by blocking VEGFR-2/3 and Tie-2 signaling [ 21 ]. We previously demonstrated that serum levels of Tie-2 were elevated in prostate cancer patients with higher Gleason scores [ 9 , 22 ]. In this study, compared with healthy controls, the serum Tie-2 level of PDAC patients was significantly increased, while the increase of the serum Tie-2 level in benign conditions was not statistically significant.…”

Section: Discussionmentioning

confidence: 99%

“…Compared with different commercial multiplex immunoassay platforms, including both plannar array and microbead assays, Meso Scale Discovery (MSD)’s MULTI-ARRAY system and Bio-Rad’s Bio-Plex system using Luminex xMAP technology were found to have the best performance with the lowest limits of detection, and the MULTI-ARRAY system had the greatest linear signal output over the widest concentration range (10 5 to 10 6 ) [ 7 , 8 ]. Previously, we successfully developed magnetic bead-based multiplex immunoassays of serum biomarkers using a Bio-Plex 200 suspension array system (Bio-Rad, Hercules, CA, USA) [ 9 , 10 , 11 , 12 ], and applied these markers to a case-control set of serum samples from subjects with PDAC or benign conditions, and healthy controls [ 11 ]. In this study, electrochemiluminescent-based multiplex immunoassays were developed for additional selected serum biomarkers using a MESO QuickPlex SQ 120 instrument (MSD, Rockville, MD, USA), and applied to a collection of patient serum samples.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays

et al. 2021

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy; its early detection is critical for improving prognosis. Electrochemiluminescent-based multiplex immunoassays were developed with high analytical performance. All proteins were analyzed in sera of patients diagnosed with PDAC (n = 138), benign pancreatic conditions (111), and healthy controls (70). The clinical performance of these markers was evaluated individually or in combination for their complementarity to CA19-9 in detecting early PDAC. Logistic regression modeling including sex and age as cofactors identified a two-marker panel of CA19-9 and CA-125 that significantly improved the performance of CA19-9 alone in discriminating PDAC (AUC: 0.857 vs. 0.766), as well as early stage PDAC (0.805 vs. 0.702) from intraductal papillary mucinous neoplasm (IPMN). At a fixed specificity of 80%, the panel significantly improved sensitivities (78% vs. 41% or 72% vs. 59%). A two-marker panel of HE4 and CEA significantly outperformed CA19-9 in separating IPMN from chronic pancreatitis (0.841 vs. 0.501). The biomarker panels evaluated by assays demonstrated potential complementarity to CA19-9 in detecting early PDAC, warranting additional clinical validation to determine their role in the early detection of pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Yet data on grey zone AG PCa identification remain limited. There are several biases for single cytokine studies, which lead to the non-comprehensive understanding of cytokines' real role in tumor diagnosis and limit their generalizability (19)(20)(21)(22). Furthermore, the progression of PCa is a multistep process involving several growth factors, hormones, and cytokines.…”

Section: Introductionmentioning

confidence: 99%

Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo identify less invasive and easily applicable serum cytokine-derived biomarkers which contribute to the diagnostic utility and risk assessment ability of the prostate health index (PHI) based multivariable model in grey zone aggressive prostate cancer (AG PCa) early detection.MethodsSerum 45 cytokines screening was performed in a small training cohort consisting of 10 sera by Luminex liquid array-based multiplexed immunoassays and identified TRAIL and IL-10 as new biomarkers for PHI diagnostic utility adjustment for further validation with a multivariable predictive model in a cohort including 79 aggressive prostate cancer patients and 209 benign prostatic hyperplasia or indolent PCa patients within the PSA grey zone.ResultsTRAIL and IL-10 were identified as potential serum biomarkers for AG PCa detection by the result of multi-cytokines screening in the univariate analysis, while multivariable logistic regression confirmed the AUC of the full risk predictive model (0.915) including tPSA, fPSA, PHI, TRAIL, and IL-10 was higher than various diagnostic strategies. DCA suggested a superior net benefit and indicated a good discriminative ability of the full risk model consistently with the result of the nomogram.ConclusionWe suggest a significant advantage for the PHI-based multivariate combinations of serum TRAIL and IL-10 comparing to PHI or other serum-derived biomarkers alone in the detection and risk stratification of grey zone AG PCa.

show abstract

“…Although a single biomarker has been identified and progressed into the clinic, molecular biomarker panels are still in the discovery stage ( Vallée et al, 2014 ). Biomarker panels consisting of various molecules are promising while genes, proteins, and metabolites work together to promote the development of cancer hallmarks, which could offer a more accurate prediction than a single biomarker ( Luo et al, 2018 ; Song et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

A Distinct Glucose Metabolism Signature of Lung Adenocarcinoma With Prognostic Value

et al. 2022

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) remains the most common type of lung cancer and is the main cause of cancer-related death worldwide. Reprogramming of glucose metabolism plays a crucial role in tumorigenesis and progression. However, the regulation of glucose metabolism is still being explored in LUAD. Determining the underlying clinical value of glucose metabolism will contribute in increasing clinical interventions. Our study aimed to conduct a comprehensive analysis of the landscape of glucose metabolism-related genes in LUAD and develop a prognostic risk signature.Methods: We extracted the RNA-seq data and relevant clinical variants from The Cancer Genome Atlas (TCGA) database and identified glucose metabolism-related genes associated with the outcome by correlation analysis. To generate a prognostic signature, least absolute shrinkage and selection operator (LASSO) Cox regression analysis was performed.Results: Finally, ten genes with expression status were identified to generate the risk signature, including FBP2, ADH6, DHDH, PRKCB, INPP5J, ABAT, HK2, GNPNAT1, PLCB3, and ACAT2. Survival analysis indicated that the patients in the high-risk group had a worse survival than those in the low-risk group, which is consistent with the results in validated cohorts. And receiver operating characteristic (ROC) curve analysis further validated the prognostic value and predictive performance of the signature. In addition, the two risk groups had significantly different clinicopathological characteristics and immune cell infiltration status. Notably, the low-risk group is more likely to respond to immunotherapy.Conclusion: Overall, this study systematically explored the prognostic value of glucose metabolism and generated a prognostic risk signature with favorable efficacy and accuracy, which help select candidate patients and explore potential therapeutic approaches targeting the reprogrammed glucose metabolism in LUAD.

show abstract

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer

Cited by 16 publications

References 51 publications

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays

Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China

A Distinct Glucose Metabolism Signature of Lung Adenocarcinoma With Prognostic Value

Contact Info

Product

Resources

About